PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of worldjgastrosurgLink to Publisher's site
 
World J Gastrointest Surg. 2010 October 27; 2(10): 368–372.
Published online 2010 October 27. doi:  10.4240/wjgs.v2.i10.368
PMCID: PMC2999204

Natural history of intraductal papillary mucinous neoplasia: How much do we really know?

Abstract

Information on the natural history of intraductal papillary mucinous neoplasia (IPMN) is currently inadequate due to a lack of carefully orchestrated long-term follow-up on a large cohort of patients with asymptomatic disease. Based on the available data, one can draw the conclusions that main duct IPMN is commonly associated with malignancy and an aggressive operative stance should be taken with resection being offered to most patients who are suitable operative candidates. In contrast, the majority of branch type IPMN with a diameter of less than 3 cm can be safely followed with routine surveillance imaging provided they lack the high-risk covariates of age, symptomatology, nodularity or wall thickness.

Keywords: Intraductal papillary mucinous neoplasia, Cystic pancreatic neoplasm, Pancreas

Natural history is defined as the “study of the natural development of a disease over a period of time”[1]. While this task for intraductal papillary mucinous neoplasm (IPMN) of the pancreas may seem straightforward, the recent recognition of IPMN as a distinct pathological entity coupled with its histopathological complexity makes this assignment exceedingly difficult. The initial description of IPMN was published in 1982[2]. However, it was not until 1996 (further clarified in 2000) that the World Health Organization formally differentiated it from other mucin-producing cystic lesions of the pancreas through a uniform classification scheme[3,4]. With this consensus nomenclature came the realization that IPMN consists of a spectrum of neoplasms (subtypes include: gastric, intestinal, pancreatobiliary and oncocytic) which show both morphological and immunohistochemical variation[5]. It is currently unknown whether these four subtypes represent distinct pathological entities (with different biological potentials) or simply histological variations along a single progressive neoplastic lineage[6]. Confounding these distinctions is the ambiguity over the exact sequence of events and the precise time frame of histopathological lesion progression from noninvasive (adenoma, borderline tumor, carcinoma-in-situ) to invasive adenocarcinoma. Even with recent data supporting the concept of clonal progression in IPMN[7], evidence substantiating a stepwise and orderly evolution by way of the adenoma to dysplasia to carcinoma sequence remains circumstantial at best[8-16]. In fact, while genetic evidence for the progression of pancreatic ductal adenocarcinoma is believed to be orderly and sequential (adenoma-carcinoma sequence), alternative theories of tumor development and progression do exist[17,18]. These differences may be explained by the recognition that not all IPMNs possess an equal potential for malignancy[19,20]. While there is broad consensus that the overall prognosis of patients with IPMN depends on the presence of invasive carcinoma, two distinct types of cancer (invasive ductal adenocarcinoma or invasive colloid carcinoma) associated with IPMN, each exhibit vastly different biological behaviors[6]. The five year survival rate in resected patients with IPMN was found to be significantly shorter (P < 0.01) in patients with invasive ductal adenocarcinoma (19%) than in patients with invasive colloid carcinoma (62%)[8]. These observations had been previously established by an independent group showing remarkably consistent findings of a five year survival rate of 12% for resected IPMN with invasive ductal adenocarcinoma vs a 57% five year survival for patients with colloid carcinoma[6,10]. These authors also found that colloid carcinoma was a favorable prognostic factor independent of patient age, tumor diameter or disease stage. Lastly, debate around the concepts of a local field defect versus disease multicentricity further clouds our understanding of the exact biology of these lesions[13,14,21-26].

As an epidemiological exercise, the ideal study to define natural history (prospective, longitudinal) would consist of a disease-free cohort undergoing continuous surveillance until they develop stage 1 disease (asymptomatic)[27]. In this idealized world, screening tests to detect disease have a sensitivity and specificity of 1.0. This cohort is then followed with periodic surveillance but without treatment until they develop stage 2 disease (symptomatic). Unfortunately, the majority of published literature on IPMN is either cohort or case-controlled studies that contain patients who have been treated (partial pancreatectomy). The overall level of evidence is poor[21]. It has been estimated, based on autopsy findings that up to 50% of all cadavers possess cystic pancreatic lesions[28]. This, coupled with the ubiquitous use of high resolution cross-sectional imaging, implies that identification of occult IPMN lesions seems likely to increase[29]. The paradox is that without properly constructed prospective observational trials at a time when the identification of IPMNs is becoming endemic, our understanding of its natural history is based solely on the extrapolation of indirect observations.

Given the limitations discussed above, a body of developing literature specifically devoted to IPMN was used as the foundation for this review. Based on these data, the natural history of IPMN lesions can be divided into two morphological subtypes: IPMN arising from the branch pancreatic ducts and IPMN arising from the main pancreatic duct. Main-duct IPMN involves and produces dilation of the duct of Wirsung. These lesions are associated with malignancy and invasive carcinoma in 43% to 70% of reported cases[21,30]. In contrast, branch-duct type IPMN lesions originate from side duct branches, do not involve the main pancreatic duct and are associated with invasive malignancy in only 15% to 25% of reported cases[13,14,31-36]. Despite the strong association between main duct IPMN and invasive adenocarcinoma, this connection does not prove causality or support any specific theory of carcinogenesis. Nevertheless, because of this strong association with malignancy, clinical exigency has resulted in consensus groups recommending operative excision of all main duct IPMNs[21,30]. These recommendations were broadened to include all “good-risk” patients with mixed-type IPMN (hybrid lesions involving both branch and main pancreatic duct)[30]. On a purely scientific note, the consequence of these proposals for aggressive resection will undoubtedly alter the landscape such that the “true” natural history of main duct IPMN may remain unknown.

In contrast to main duct IPMN, branch duct variants have significantly more published literature from which to make indirect inferences regarding their natural history. Approximately 90% of all lesions presumed to be IPMN (lacking definitive pathological analysis) which have undergone a period of surveillance without treatment have been branch duct variants[21]. Due to this wealth of surveillance data, a greater number of covariates have been identified in branch duct type IPMN that are associated with malignancy when compared to main duct IPMN. Tumor factors such as the size of a branch duct lesion (> 3 cm in cross-sectional diameter)[8,30,32,37-39], radiological characteristics (wall thickness or mural nodules)[37,40-43] or the presence of symptoms (jaundice, steatorrhea, new onset diabetes)[15,40,44] have all correlated with a higher incidence of associated invasive carcinoma. While lesions greater than 3 cm and the presence of mural nodules are associated with concurrent malignancy rates in resected patients of up to 82%, there is continued debate as to the utility of this measure to reliably predict tumor behavior[40,42,45]. In those series where invasive malignancy in branch duct IPMNs were not correlated with size, all had a high percentage of symptomatic patients, a known confounding variable, in their cohort[40,42,45]. Alternatively, the invasive malignancies identified in these patients might be synchronous malignancy at a site distant from the IPMN[46]. Broadly, it appears that the incidence of malignancy increases proportionately to the number of patients in the series with symptoms[8,13,38,39]. In point of fact, there are no known biological systems with sharp size “cutoffs”. In this context, 3 cm likely constitutes an arbitrary threshold within a large continuum. Given these data, the natural history of branch duct IPMN is more aggressive in patients who present with symptoms, display mural nodules and/or solid components on imaging or possess lesions greater than 3 cm in cross-sectional diameter.

Patient age at the time of diagnosis represents another covariate in the natural history of IPMN. Resected patients with malignant IPMN are older than resected patients with benign IPMN[8,13-15]. On average, patients with malignant (invasive) IPMN are approximately 5 years older than patients with benign (adenoma or borderline) IPMN[8,14,15]. Of interest in this observation is the finding of an increased incidence of dysplastic changes in the lesions of older patients with IPMN[13]. Both observations lend weak indirect support to the theory of sequential genetic alterations consistent with clonal progression[7]. While age at the time of diagnosis is indirect evidence, non-operative surveillance of IPMN is the gold standard for defining natural history. The cumulative published experience of surveilling 450 patients with presumed branch duct IPMN using serial imaging and clinical examination indicates that very few asymptomatic, small (< 3 cm), branch duct lesions either enlarge (6% to 12%) or progress to invasive malignancy[16,19,21,35,36,39,47-51]. In these observations, the frequent lack of a firm histopathological tissue diagnosis also obscures the generalizability of these data. In addition, all have relatively short mean follow-up periods (maximum 40 mo) further complicating the interpretation of a neoplasm with a known indolent course. Following operation, the risk of recurrence in either the remnant pancreas or distant sites is high (up to 65%) in patients with invasive IPMN[13,14,21-23]. This rate is substantially lower (< 8%) in patients with noninvasive IPMN (adenoma, dysplasia, carcinoma in situ)[13,14,21-23].

In summary, the current literature regarding the natural history of IPMN is limited by selection bias (mostly resected patients), unclear definitions, varying inclusion criteria, heterogeneous patient groups, small nonoperative surveillance cohorts and relatively short follow-up periods[52,53]. Although these issues challenge our ability to accurately define the natural history of IPMN, it is clear that main duct IPMN at the time of its diagnosis commonly co-exists with malignancy. These lesions should be resected when identified in patients who are suitable operative candidates since their risk of occult malignancy far outweighs their operative risk, even for pancreaticoduodenectomy. The clinical decision making for branch duct IPMN is more complex. To fully evaluate risk/benefit ratios in these patients, one must consider patient age, symptoms, lesion size, radiological findings, type of operation and the ability of a patient to potentially engage in a lengthy surveillance program. Most branch duct IPMN are currently being identified with a diameter of less than 3 cm, a size which, given the lack of other high risk covariates (age, symptoms, nodularity, thick wall), can be safely surveilled[54]. Only with the combination of long periods of observation and direct evidence of true malignant transformation (or lack thereof) will we be able to better define the natural history of IPMN.

Footnotes

Peer reviewers: Runjan Chetty, MB, BCh, Professor, Department of Pathology, University of Glasgow, McGregor Building, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, United Kingdom; Shailesh V Shrikhande, MS, MD, Professor, Department of Gastrointestinal and Hepato-Pancreato-Biliary Surgery, Tata Memorial Hospital Ernest Borges Marg, Parel, Mumbai 400012, India

S- Editor Wang JL L- Editor Roemmele A E- Editor Ma WH

References

2. Ohashi K, Murakami Y, Takekoski T. Four cases of ‘mucin producing’ cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc. 1982;20:348–351.
3. Klöppel G, Solcia E, Longnecker DS. Histologic typing of tumors of the exocrine pancreas. In: World Health Organization ed., editor. International Classification of Tumors. 2nd ed. Berlin: Springer; 1996. pp. 11–20.
4. Longnecker DS, Adler G, Hruban RH, Klöppel G. Intraductal papillary mucinous neoplasms of the pancreas. In: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. Lyon, IARC Press; 2000. pp. 237–241.
5. Furukawa T, Klöppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–799. [PubMed]
6. Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, Goggins M, Iocobuzio-Donahue C, Longnecker DS, Klimstra DS. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15:1087–1095. [PubMed]
7. Wada K, Takada T, Yasuda H, Amano H, Yoshida M, Sugimoto M, Irie H. Does “clonal progression” relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg. 2004;8:289–296. [PubMed]
8. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788–797; discussion 797-799. [PubMed]
9. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 2003;24:193–198. [PubMed]
10. Adsay NV. The "new kid on the block": Intraductal papillary mucinous neoplasms of the pancreas: current concepts and controversies. Surgery. 2003;133:459–463. [PubMed]
11. Yanagisawa A, Kato Y, Ohtake K, Kitagawa T, Ohashi K, Hori M, Takagi K, Sugano H. c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn J Cancer Res. 1991;82:1057–1060. [PubMed]
12. Loftus EV Jr, Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG, DiMagno EP. Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology. 1996;110:1909–1918. [PubMed]
13. Bernard P, Scoazec JY, Joubert M, Kahn X, Le Borgne J, Berger F, Partensky C. Intraductal papillary-mucinous tumors of the pancreas: predictive criteria of malignancy according to pathological examination of 53 cases. Arch Surg. 2002;137:1274–1278. [PubMed]
14. Yamao K, Ohashi K, Nakamura T, Suzuki T, Shimizu Y, Nakamura Y, Horibe Y, Yanagisawa A, Nakao A, Nimuara Y, et al. The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology. 2000;47:1129–1134. [PubMed]
15. Salvia R, Fernández-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–685; discussion 685-687. [PubMed]
16. Lévy P, Jouannaud V, O'Toole D, Couvelard A, Vullierme MP, Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol. 2006;4:460–468. [PubMed]
17. Irie H, Yoshimitsu K, Aibe H, Tajima T, Nishie A, Nakayama T, Kakihara D, Honda H. Natural history of pancreatic intraductal papillary mucinous tumor of branch duct type: follow-up study by magnetic resonance cholangiopancreatography. J Comput Assist Tomogr. 2004;28:117–122. [PubMed]
18. Lahav M, Maor Y, Avidan B, Novis B, Bar-Meir S. Nonsurgical management of asymptomatic incidental pancreatic cysts. Clin Gastroenterol Hepatol. 2007;5:813–817. [PubMed]
19. Bassi C, Sarr MG, Lillemoe KD, Reber HA. Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg. 2008;12:645–650. [PubMed]
20. Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500–1507. [PubMed]
21. Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nishio K, Nagao M, Ikeda N, Kanokogi H, Yamada T, Nakano H. Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas. World J Surg. 1998;22:874–878. [PubMed]
22. Kaneko T, Nakao A, Inoue S, Sugimoto H, Hatsuno T, Ito A, Hirooka Y, Nagasaka T, Nakashima N. Intraoperative ultrasonography by high-resolution annular array transducer for intraductal papillary mucinous tumors of the pancreas. Surgery. 2001;129:55–65. [PubMed]
23. Kaneko T, Nakao A, Nomoto S, Furukawa T, Hirooka Y, Nakashima N, Nagasaka T. Intraoperative pancreatoscopy with the ultrathin pancreatoscope for mucin-producing tumors of the pancreas. Arch Surg. 1998;133:263–267. [PubMed]
24. Fujii T, Obara T, Maguchi H, Tanno S, Ura H, Kohgo Y. Clinicopathological study of mucin-producing tumors of the pancreas: multicentric development of carcinoma through atypical hyperplasia. Suizou J Jpn Pancreatol Soc. 1996;11:344–352.
25. Brookmeyer R. Statistical problems in epidemiologic studies of the natural history of disease. Environ Health Perspect. 1990;87:43–49. [PMC free article] [PubMed]
26. Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y. Analysis of small cystic lesions of the pancreas. Int J Pancreatol. 1995;18:197–206. [PubMed]
27. Messersmith WA, Brown DF, Barry MJ. The prevalence and implications of incidental findings on ED abdominal CT scans. Am J Emerg Med. 2001;19:479–481. [PubMed]
28. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32. [PubMed]
29. Kobari M, Egawa S, Shibuya K, Shimamura H, Sunamura M, Takeda K, Matsuno S, Furukawa T. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg. 1999;134:1131–1136. [PubMed]
30. Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, Bernades P, Belghiti J, Ruszniewski P, Fléjou JF. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol. 2000;24:1372–1377. [PubMed]
31. Falconi M, Salvia R, Bassi C, Zamboni G, Talamini G, Pederzoli P. Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg. 2001;88:376–381. [PubMed]
32. Zamora C, Sahel J, Cantu DG, Heyries L, Bernard JP, Bastid C, Payan MJ, Sielezneff I, Familiari L, Sastre B, et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature. Am J Gastroenterol. 2001;96:1441–1447. [PubMed]
33. Yamaguchi K, Sugitani A, Chijiiwa K, Tanaka M. Intraductal papillary-mucinous tumor of the pancreas: assessing the grade of malignancy from natural history. Am Surg. 2001;67:400–406. [PubMed]
34. Wakabayashi T, Kawaura Y, Morimoto H, Watanabe K, Toya D, Asada Y, Satomura Y, Watanabe H, Okai T, Sawabu N. Clinical management of intraductal papillary mucinous tumors of the pancreas based on imaging findings. Pancreas. 2001;22:370–377. [PubMed]
35. Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology. 2008;135:724–728. [PubMed]
36. Schneider BL, Kulesz-Martin M. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis. 2004;25:2033–2044. [PubMed]
37. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK. MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol. 2006;186:687–695. [PubMed]
38. Kitagawa Y, Unger TA, Taylor S, Kozarek RA, Traverso LW. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg. 2003;7:12–18; discussion 18-19. [PubMed]
39. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003;90:1244–1249. [PubMed]
40. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 2007;246:644–651; discussion 651-654. [PubMed]
41. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T. Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg. 2007;11:338–344. [PubMed]
42. Serikawa M, Sasaki T, Fujimoto Y, Kuwahara K, Chayama K. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. J Clin Gastroenterol. 2006;40:856–862. [PubMed]
43. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Namikawa T, Okamoto K, Okamoto N, Kosaki T, Onishi S, Araki K. Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol. 2006;21:462–467. [PubMed]
44. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 2007;133:72–79; quiz 309-310. [PubMed]
45. Waters JA, Schmidt CM. Intraductal papillary mucinous neoplasm--when to resect? Adv Surg. 2008;42:87–108. [PubMed]
46. Kobayashi G, Fujita N, Noda Y, Ito K, Horaguchi J, Takasawa O, Akaishi S, Tsuchiya T, Kobari M. Mode of progression of intraductal papillary-mucinous tumor of the pancreas: analysis of patients with follow-up by EUS. J Gastroenterol. 2005;40:744–751. [PubMed]
47. Suzuki Y, Atomi Y, Sugiyama M, Isaji S, Inui K, Kimura W, Sunamura M, Furukawa T, Yanagisawa A, Ariyama J, et al. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas. 2004;28:241–246. [PubMed]
48. Matsumoto T, Aramaki M, Yada K, Hirano S, Himeno Y, Shibata K, Kawano K, Kitano S. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol. 2003;36:261–265. [PubMed]
49. Obara T, Maguchi H, Saitoh Y, Ura H, Koike Y, Kitazawa S, Namiki M. Mucin-producing tumor of the pancreas: a unique clinical entity. Am J Gastroenterol. 1991;86:1619–1625. [PubMed]
50. Salvia R, Crippa S, Falconi M, Bassi C, Guarise A, Scarpa A, Pederzoli P. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut. 2007;56:1086–1090. [PMC free article] [PubMed]
51. Allen PJ, D'Angelica M, Gonen M, Jaques DP, Coit DG, Jarnagin WR, DeMatteo R, Fong Y, Blumgart LH, Brennan MF. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2006;244:572–582. [PubMed]
52. Carpizo DR, Allen PJ, Brennan MF. Current management of cystic neoplasms of the pancreas. Surgeon. 2008;6:298–307. [PubMed]
53. Waters JA, Schmidt CM. Intraductal papillary mucinous neoplasm--when to resect? Adv Surg. 2008;42:87–108. [PubMed]
54. Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA. Cystic pancreatic neoplasms: observe or operate. Ann Surg. 2004;239:651–657; discussion 657-659. [PubMed]

Articles from World Journal of Gastrointestinal Surgery are provided here courtesy of Baishideng Publishing Group Inc